Zura Bio (ZURA) and Its Rivals Financial Survey

Zura Bio (NASDAQ:ZURA) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Zura Bio to similar companies based on the strength of its analyst recommendations, institutional ownership, valuation, risk, dividends, profitability and earnings.

Volatility & Risk

Zura Bio has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500. Comparatively, Zura Bio’s peers have a beta of -3.86, suggesting that their average share price is 486% less volatile than the S&P 500.

Earnings and Valuation

This table compares Zura Bio and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zura Bio	N/A	-$69.24 million	-2.24
Zura Bio Competitors	$574.62 million	-$70.96 million	0.12

Zura Bio’s peers have higher revenue, but lower earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 22.1% of Zura Bio shares are owned by company insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Zura Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-37.36%	-29.81%
Zura Bio Competitors	-2,185.76%	-161.46%	-40.62%

Analyst Recommendations

This is a breakdown of current recommendations for Zura Bio and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	0	1	6	1	3.00
Zura Bio Competitors	1925	5386	13951	296	2.59

Zura Bio currently has a consensus target price of $15.00, indicating a potential upside of 1,165.82%. As a group, “Biological products, except diagnostic” companies have a potential upside of 116.66%. Given Zura Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Zura Bio is more favorable than its peers.

Summary

Zura Bio beats its peers on 11 of the 13 factors compared.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.